(Q38594067)

4 September 2017

Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics (English)

1 reference

4 September 2017

0 references

5

Anne Greenough

0 references

Asuncion Mejias

Asuncion Mejias

8

0 references

Federico Martinón-Torres

Federico Martinón-Torres

2

0 references

Shabir A. Madhi

15

Shabir A Madhi

1 reference

4 September 2017

Mike Sharland

13

0 references

Harish Nair

9

Harish Nair

1 reference

4 September 2017

6

Terho Heikkinen

1 reference

4 September 2017

Natalie I Mazur

1

1 reference

4 September 2017

Eugenio Baraldi

3

1 reference

4 September 2017

Brigitte Fauroux

4

1 reference

4 September 2017

Paolo Manzoni

7

1 reference

4 September 2017

Nikolaos G Papadopoulos

10

1 reference

4 September 2017

Fernando P Polack

11

1 reference

4 September 2017

Octavio Ramilo

12

1 reference

4 September 2017

Renato Stein

14

1 reference

4 September 2017

Louis Bont

16

1 reference

4 September 2017

Respiratory Syncytial Virus Network (ReSViNET)

17

1 reference

4 September 2017

24 September 2015

1 reference

The Lancet. Respiratory medicine

4 September 2017

1 reference

4 September 2017

3

1 reference

4 September 2017

888-900

1 reference

4 September 2017

11

1 reference

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Direct medical costs of bronchiolitis hospitalizations in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

The burden of respiratory syncytial virus infection in young children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

The role of early life viral bronchiolitis in the inception of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Determinants of asthma after severe respiratory syncytial virus bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Diagnosis, management, and prognosis of preschool wheeze

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Duration of symptoms of respiratory tract infections in children: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Frequent Asymptomatic Respiratory Syncytial Virus Infections During an Epidemic in a Rural Kenyan Household Cohort

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Bronchodilators for bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Glucocorticoids for acute viral bronchiolitis in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Epinephrine for bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Diagnosis and management of bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Failure of high-flow nasal cannula therapy may delay intubation and increase mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Failure of high-flow nasal cannula and delayed intubation: a new harmful sequence?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Grading quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Medicines used in respiratory diseases only seen in children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Nebulised hypertonic saline solution for acute bronchiolitis in infants

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Bronchiolitis management before and after the AAP guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Oral GS-5806 activity in a respiratory syncytial virus challenge study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Strategic priorities for respiratory syncytial virus (RSV) vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Pharmacologic advances in the treatment and prevention of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

Identification of nucleolin as a cellular receptor for human respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2815%2900255-6

7 January 2021

10.1016/S2213-2600(15)00255-6

Identifiers

DOI

1 reference

4 September 2017

1 reference